drugset
drugset / Trial / NCT02279745

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745 ↗

Phase 2 Completed 45 enrolled United Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinued due to clinical worsening.

Timeline

Start
2015-07-08
Primary completion
2021-03-29
Completion
2021-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ralinepag Small molecule 10 ug Oral
Subject Ralinepag Small molecule 20 ug Oral
Subject Ralinepag Small molecule 30 ug Oral
Subject Ralinepag Small molecule 40 ug Oral
Subject Ralinepag Small molecule 50 ug Oral
Subject Ralinepag Small molecule 100 ug Oral
Subject Ralinepag Small molecule 250 ug Oral
Subject Ralinepag Small molecule 400 ug Oral

Indications

pulmonary arterial hypertension